Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Healthcare Drug Manufacturers - Major Cannabis
Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Aphria Inc. > Q4 Projections
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(87)
•••
Post by arblineson Jun 10, 2020 7:51am
300 Views
Post# 31132144

Q4 Projections

Q4 Projections
My best optimistic guess will be:

100 mil distribution, with 5 mil EBITDA; and

67.5 mil MJ sales with 40 mil EBITDA. This number is based on 15% MS and 150 mil average monthly MJ sales.

This should total 167.5 mil in Revenue, for 557.5 mil in revenue in FY2019 --- just 20 mil short of their forecast.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities